Search results :

Milnacipran

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: N06AX17

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4
Nausea 1.5% - 39% 6% - 20% x x x x
Headache 17% - 19% 14% x x x
Constipation 9% - 16% 3% - 4% x x x x
Hot flush 3% - 12% 1% - 2% x x x x
Insomnia 12% 10% x x x
Dizziness 10% - 11% 6% x x x
Hyperhidrosis 8% - 9% 2% x x x x
Palpitations 5% - 8% 1% - 2% x x x x
Vomiting 5% - 7% 1% - 2% x x x x
Erectile dysfunction 6% - 10% 1% - 2% x x x x
Upper respiratory tract infection 6% - 7% 6% x x x
Hypertension 3% - 7% 1% - 2% x x x x
Tachycardia 2% - 6% 1% - 2% x x x x
Dry mouth 5% 2% x x x
Migraine 4% - 6% 3% x x x x
Ejaculation disorder 5% 1% x x x x
Urinary hesitation 4% - 6% 0% x x x x
Anxiety 3% - 5% 4% x x x
Testicular pain 4% 1% x x x x
Abdominal pain 3% 2% x x x x
Rash 2% - 4% 0% - 2% x x x x
Flushing 2% - 3% 1% x x x
Hypotension 3% 1% x
Blood pressure increased 3% 1% x x x x
Chest pain 2% - 3% 2% x x x x
Dyspnoea 2% 1% x x x
Paraesthesia 2% - 3% 2% x x x x
Pruritus 2% - 3% 2% x x x x
Tremor 2% 1% x x x
Chills 1% - 2% 0% x x x
Decreased appetite 1% - 3% 0% - 1% x x x x
Vision blurred 1% - 2% 1% x x x x
Hypoaesthesia 1% - 2% 1% x x x
Tension headache 1% - 2% 1% x x x
Chest discomfort 1% - 2% 1% x x x
Aggression postmarketing x x
Anger postmarketing x x
Anorexia postmarketing x x x
Mental disorder postmarketing x x x x
Breast disorder postmarketing x x x x
Connective tissue disorder postmarketing x x x
Delirium postmarketing x x x
Endocrine disorder postmarketing x x x
Erythema multiforme postmarketing x x x
Eye disorder postmarketing x x x x
Hallucination postmarketing x x x
Cardiac disorder postmarketing x x x x
Hepatitis postmarketing x x x
Hyperprolactinaemia postmarketing x x x
Hypertensive crisis postmarketing x x x
Hyponatraemia postmarketing x x x x
Renal failure acute postmarketing x x x
Leukopenia postmarketing x x x
Nervous system disorder postmarketing x x x x
Neuroleptic malignant syndrome postmarketing x
Neutropenia postmarketing x x x
Rhabdomyolysis postmarketing x x x
Convulsion postmarketing x x x x
Skin disorder postmarketing x x x
Stevens-Johnson syndrome postmarketing x x x
Supraventricular tachycardia postmarketing x x x
Thrombocytopenia postmarketing x x x
Loss of consciousness postmarketing x x x
Urinary tract disorder postmarketing x x x x
Angiopathy postmarketing x x x x
Accommodation disorder postmarketing x x x
Malnutrition postmarketing x x x x
Galactorrhoea postmarketing x x x
Parkinsonism postmarketing x x x
Hepatobiliary disease postmarketing x x x
Homicidal ideation postmarketing x
Serotonin syndrome postmarketing x x
Blood and lymphatic system disorders postmarketing x x x
Abdominal distension x x x
Angina pectoris x
Bruxism x
Infection x x x
Conjunctival haemorrhage x
Contusion x x x
Cystitis x x x
Libido decreased x x x
Diarrhoea x x x
Dysgeusia x x x
Dyspepsia x x x
Dysuria x x x
Extrapyramidal disorder x
Fatigue x x x
Body temperature increased x x x
Flatulence x x x x
Gastrooesophageal reflux disease x x x
Gastrointestinal disorder x x x x
Angle closure glaucoma x
Haematuria x
Hypercholesterolaemia x x x
Hypersensitivity x
Irritability x x x
Mediastinal disorder x
Night sweats x x x
Prostatitis x x x
Proteinuria x
Syncope x
Thirst x
Pollakiuria x
Urinary tract infection x x x
Urticaria x
Weight decreased x x x
Yawning x
Urinary retention x x x
Agitation x
Oedema peripheral x x x
Panic attack x
Ventricular extrasystoles x
Liver function test abnormal x
Urethral pain x x x
Dry skin x
Unspecified disorder of skin and subcutaneous tissue x
Tension x
Scrotal pain x x x
Hypomania x
Ejaculation failure x x x
Dry eye x
Mania x
Suicidal ideation x
Urine flow decreased x x x
Blood cholesterol increased x
Hemorrhage abnormal x
Testicular swelling x x x
Somnolence x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

levomilnacipran

Side effects:64
Source:FDA Structured Product Label

milnacipran

Side effects:95
Source:FDA Structured Product Label

MILNACIPRAN

Side effects:97
Source:FDA Structured Product Label

milnacipran

Side effects:98
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label